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J Sex MedIntroduction: Several hormones and neurotransmitters orchestrate men’s sexual response, including the appe-
titive (sexual desire) and consummative (arousal and penile erection) phases.
Aim: To provide an overview and recommendations regarding endocrinologic control of sexual desire and arousal
and erection and their disturbances.
Methods: Medical literature was reviewed by the subcommittee of the International Consultation of Sexual
Medicine, followed by extensive internal discussion, and then public presentation and discussion with other
experts. The role of pituitary (prolactin, oxytocin, growth hormone, and a-melanocyte-stimulating hormone),
thyroid, and testicular hormones was scrutinized and discussed.
Main Outcome Measures: Recommendations were based on grading of evidence-based medical literature,
followed by interactive discussion.
Results: Testosterone has a primary role in controlling and synchronizing male sexual desire and arousal, acting
at multiple levels. Accordingly, meta-analysis indicates that testosterone therapy for hypogonadal individuals can
improve low desire and erectile dysfunction. Hyperprolactinemia is associated with low desire that can be suc-
cessfully corrected by appropriate treatments. Oxytocin and a-melanocyte-stimulating hormone are important in
eliciting sexual arousal; however, use of these peptides, or their analogs, for stimulating sexual arousal is still under
investigation. Evaluation and treatment of other endocrine disorders are suggested only in selected cases.
Conclusion: Endocrine abnormalities are common in patients with sexual dysfunction. Their identification and
treatment is strongly encouraged in disturbances of sexual desire and arousal.
J Sex Med 2016;13:317e337. Copyright  2016, International Society for Sexual Medicine. Published by Elsevier
Inc. All rights reserved.
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Cells communicate with one another through a discrete flow of
molecules that consistently influence their behavior and activity.
Two distinct classes of communicating molecules are recognizedptember 29, 2015. Accepted January 15, 2016.
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2016;13:317e337and classified according to their origin and fate: neurotransmitters
and hormones. Hormones often are derived from endocrine glands
and reach their target cells through the bloodstream, whereas
neurotransmitters are locally generated and bioactive within the
synaptic cleft. However, some communicating molecules often act
as a neurotransmitter or as a hormone (eg, noradrenaline, OT, and
a-MSH). Any interference with endocrine cell-to-cell communi-
cation because of over- (hyper-) or under- (hypo-) flow results in
pathologic conditions. Because communication is very important
in the dyadic field of sexual medicine, it obvious that endocrine
disorders can greatly affect the sexual brain (desire) and the sexual
body (arousal and erection).
This article presents a summary of the main endocrine
control of men’s sexual desire and arousal and erection as
discussed by the authors at their presentation at the Fourth
International Consultation of Sexual Medicine (Madrid,
Spain, June 2015). After the past three International Con-
sultations on Sexual Medicine, significant advances in the
understanding of the endocrinology of male sexual function317
RECOMMENDATIONS
Recommendation 1
 Testosterone (T) significantly contributes to the regulation of male sexual desire (level 1A), and T treatment (TTh) can improve
libido in hypogonadal (total T < 12 nmol/L) men (level 1A).
 T evaluation is strongly recommended in all men complaining of decreased sexual desire (level 1A).
Recommendation 2
 Dihydrotestosterone (DHT) and estrogens play a minor role in the regulation of male sexual desire (level 2B).
 DHT and estradiol (E2) evaluations are not recommended in men complaining of decreased sexual desire (level 3B).
Recommendation 3
 Adrenal hormones, including dehydroepiandrosterone (DHEA) and its sulfate (DHEAS; level 2A), and cortisol and aldosterone
(level 3B) are not involved in the regulation of male sexual desire.
 Adrenal hormone evaluation is not recommended in men complaining of decreased sexual desire (level 1A).
Recommendation 4
 Prolactin (PRL) plays a major role in regulating male sexual desire (level 2A), acting through direct and indirect pathways (level 3B).
 PRL levels should be evaluated in all men complaining of decreased sexual desire (level 2A).
 Treating hyperprolactinemia restores sexual desire (level 2A).
Recommendation 5
 The contribution of thyroid hormones (THs) in the regulation of male sexual desire is contradictory (level 3B).
 TH evaluation is not recommended in men complaining of decreased sexual desire (level 2B).
Recommendation 6
 T regulates penile development and growth in early life, but not after puberty (level A).
 T targets several molecular pathways involved in the physiology of erections, including the nitric oxide and cyclic guanosine
monophosphate (NO-cGMP) pathway (level A), RhoA-ROCK signaling, adrenergic response, and cavernous smooth muscle
cell (SMC) turnover (level B).
Recommendation 7
 The decrease of circulating T levels is associated with a decrease in erectile function (EF; level 2B).
 TTh in hypogonadal men (total T level< 12 nmol/L) is associated with significant increases in self-reported measurements of EF
that are proportional to the severity of hypogonadal status before treatment (level 1A).
 Basal and longitudinal assessments of T are recommended in men with erectile dysfunction (ED; level 1A).
Recommendation 8
 DHT exerts qualitatively similar effects as T on EF (level 2A), although it has been studied less extensively.
 Treatment with DHT and its analogs (mesterolone) cannot be recommended as an alternative to TTh to improve EF in
hypogonadal men (level 4B).
 Measurement of DHT is not recommended in the assessment of EF (level 3A).
Recommendation 9
 The role of E2 on EF is controversial. Experimental evidence indicates that E2 downregulates phosphodiesterase type 5
(PDE5) expression (level 3C).
 Measurement of estrogens is not recommended in the assessment of EF (level 2C).
Recommendation 10
 DHEA and DHEAS are not involved in the regulation of male EF (level 2A).
 Glucocorticoid and mineralocorticoid in adrenal insufficiency might play a role in restoring EF (level 4C).
Recommendation 11
 PRL does not play a direct role in the regulation of male EF (level 3B).
 PRL evaluation is not recommended in patients complaining of ED (level 2B).
 Treating hyperprolactinemia might have indirect, positive effects on arousal and erection (level 3B)
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Recommendation 12
 Conclusive data regarding the potential therapeutic role of oxytocin (OT) in male sexual dysfunctions are lacking (level 2B).
Recommendation 13
 Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are not involved in the regulation of male EF (level 3B).
 GH and IGF-1 levels should not be evaluated in men complaining of ED (level 2B).
Recommendation 14
 Animal models indicate that the melanocortin system is involved in the regulation of EF acting at a central level (level 2C).
 Available randomized controlled trials (RCTs) do not suggest analogs of a-melanocyte-stimulating hormone (a-MSH) for the
treatment of ED because of associated adverse events (level 1B).
Recommendation 15
 Hyperthyroidism is significantly associated with an increased risk of ED (level 3B).
 Treating hyperthyroidism improves ED (level 3B).
 Sexual function should be assessed in all men with hyperthyroidism (level 3B).
 The prevalence of hyperthyroidism in men seeking medical care for ED is low (level 2B).
 TH evaluation is not recommended in all men complaining of ED (level 2B).
 The association between hypothyroidism and impairment of EF is contradictory (level 2C).
 Sexual function should not be assessed in all men with hypothyroidism (level 2B).
 The prevalence of hypothyroidism in men seeking medical care for ED is low (level 2B).
 TH evaluation is not recommended in all men complaining of ED (level 2B).
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dations focusing on the pathophysiology of male sexual dys-
functions, specifically on the endocrine aspects. In particular,
the aim of this article was to scrutinize studies analyzing the
effect of hormone alterations, and their treatments, on sexual
desire and arousal and erection.Figure 1. Sites of action of testosterone and prolactin in regulating
male sexual desire and arousal and erection. Adapted from Isidori
et al.75 Figure 1 is available in color online at www.jsm.jsexmed.org.HORMONES AND SEXUAL DESIRE
Sex steroids (T, DHT, and E2)
There is much evidence documenting T as the fuel of male
sexual desire.1e7 However, the contribution of T in the age-
related decline of male sexual desire is contradictory, at least in
the general population. The Olmsted Longitudinal Study,5 a
stratified random sample of 414 men, failed to find any associ-
ation between total T and sexual desire after adjusting for age.
The Massachusetts Male Aging Study (MMAS)6 found only a
modest difference in mean T levels between subjects with and
without low libido (0.12 nmol/L). In contrast to these reports,
the European Male Aging Study (EMAS), a population-based
survey performed on more than 3,400 men recruited from
eight European centers,7 clearly showed that a decreased fre-
quency of sexual thoughts is one of the more specific symptoms
associated with T deficiency. However, it is important to
emphasize that the same study showed that the simultaneous
presence of three sexual symptoms (low sexual desire, decreased
morning erections, and ED) was the strongest predictor of
low T, suggesting that sexual symptoms, in this combination,
are the most sensitive and specific in identifying patientsJ Sex Med 2016;13:317e337with low T levels.7 Similar results were reported more recently
by the Testosterone Trials (TTrials),8 a survey performed in
788 community-dwelling men recruited from 12 sites in the
United States. In addition, the Concord Health and Aging in
Men Projects (CHAMP),9 a prospective population-based
observational study enrolling 1,226 men older than 70 years
and followed for 2 years, found a consistent association between
the decrease of T and the decrease of sexual desire. In particular,
Table 1. Characteristics and Outcomes of Randomized, Placebo-Controlled Clinical Studies Included in Meta-Analysis*
Study
Patients
(T/placebo), n
Trial
duration
(wk) Age (y) T levels Dose (daily) Design
Sexual function
tool used EF domain Libido domain
Eugonadal
O’Carroll and
Bancroft,12
1984
20/20 12 19e64 Eugonadal Sustanon 250 mg/
2 wk
Crossover Specific questions
on sexual
function
0.13 (1.73 to 1.48),
P ¼ .88†; 0.34
(0.59 to 1.27),
P ¼ .48‡
0.79 (0.23 to 1.81),
P ¼ .13†; 0.09
(0.83 to1.02),
P ¼ .84‡
Anderson et al,13
1992
16/15 4 21e41 Eugonadal TE 200 mg/wk parallel SES score 0.20 (0.91 to
0.51), P ¼ .58
0.08 (0.62 to
0.78), P ¼ .82
Aydin et al,126
1996
20/18 8 36.8 Eugonadal TU 160 mg/d Parallel Specific questions
on sexual
function
0.16 (0.57 to 0.89),
P ¼ .67
—
Svartberg et al,14
2004
15/14 26 54e75 Eugonadal TE 250 mg/mo Parallel IIEF-5 0.90 (0.06e1.74),
P ¼ .04
—
Overall eugonadal 0.22 (0.17 to 0.61),
P ¼ .26
0.25 (0.24 to 0.74),
P ¼ .32
Mixed
Benkert et al,127
1979
13/16 8 45e75 Eugonadal TU 120 mg/d Parallel CGI scale 0.26 (1.08 to
0.56), P ¼ .54
—
Gluud et al,15
1988
64/46 30 24e79 Mixed TU 400 mg/d Parallel Specific questions
on sexual
function
0.27 (0.11 to 0.65),
P ¼ .17
0.20 (0.18 to 0.58),
P ¼ .31
Schiavi et al,16
1997
7/5 6 46e67 Mixed TE 200 mg/2 wk Crossover BSF score 0.00 (1.15 to 1.15),
P ¼ 1.00
2.40 (0.90e3.90), P
< .0001
Rabkin et al,17
2000
39/35 6 67.7 ± 3.8 Mixed TC 200 mg/2 wk Parallel CGI scale — 0.76 (0.27e1.24), P
< .0001
Haren et al,18
2005
39/37 48 68.5 ± 6.0 Mixed TU 160 mg/d Parallel ADAM
questionnaire
0.28 (0.55 to 1.11),
P ¼ .51
0.50 (0.04e0.95),
P ¼ .03
Overall mixed 0.18 (0.13 to 0.48),
P ¼ .26
0.64 (0.14e1.13),
P ¼ .01
Hypogonadal
Nankin et al,19
1986
10/10 12 51e72 <12 nmol/L TC 200 mg/2 wk Crossover Specific questions
on sexual
function
— 0.50 (0.39 to 1.39),
P ¼ .27
Dobs et al,20
1998
7/6 8 41 ± 16 <8 nmol/L Buccal T 10e20
mg/d
Parallel WSF score — 0.67 (0.45 to 1.79),
P ¼ .24
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Table 1. Continued
Study
Patients
(T/placebo), n
Trial
duration
(wk) Age (y) T levels Dose (daily) Design
Sexual function
tool used EF domain Libido domain
Seidman et al,128
2001
13/17 6 35e71 <12 nmol/L TE 200 mg/wk Parallel DSPS-M 0.91 (0.15e1.67),
P ¼ .02
—
Steidle et al,21
2003, Seftel
et al,22 2004
106/99 40 56.8 ± 10.6 <12 nmol/L TG 100 mg/d Parallel Specific questions
on sexual
function
0.29 (0.01e0.56),
P ¼ .04
0.36 (0.09e0.64),
P ¼ .01
Cavallini et al,23
2004
40/45 24 60e72 <12 nmol/L TU 160 mg/d parallel IIEF-15 7.00 (5.86e8.14),
P < .0001
4.00 (3.25e4.75),
P < .0001
Chiang et al,30
2007
20/18 12 20e75 <12 nmol/L TG 50 mg/d Parallel IIEF-EF score 0.40 (0.26 to 1.05),
P ¼ .23
—
Jones et al,24
2011
103/102 52 59.9 ± 9.3 <12 nmol/L TG 60 mg/d Parallel IIEF-15 0.08 (0.21 to 0.37),
P ¼ .59
0.21 (0.08 to 0.50),
P ¼ .15
Hackett et al,25
2013
92/98 30 33e83 <12 nmol/L TU 1,000 mg/12
wk
Parallel IIEF-15 0.33 (0.04e0.62),
P ¼ .03
0.31 (0.02e0.59),
P ¼ .04
Francomano
et al,130 2014
20/20 240 57.5 <12 nmol/L TU 1,000 mg/12
wk
Parallel IIEF-EF score 1.03 (0.37e1.69),
P < .0001
—
Overall total T < 12 nmol/L 0.29 (0.01e0.56),
P ¼ .04
0.97 (0.22e1.71),
P ¼ .04
Skakkebaek
et al,26 1981
7.00 (5.86
e8.14),
P < .0001
7.00 (5.86
e8.14),
P < .0001
22e50 <8 nmol/L TU 160 mg/d Crossover Specific questions
on sexual
function
1.76 (0.78e2.75),
P < .0001
1.46 (0.52e2.40), P
< .0001
Bancroft and
Wu,27 1983
8/8 8 21e57 <8 nmol/L TU 160 mg/d Crossover Specific questions
on sexual
function and
real-time NPT
— 0.97 (0.07 to 2.01),
P ¼ .07
Carani et al,28
1990
6/6 6 21e57 <8 nmol/L TU 160 mg/d Crossover Specific questions
on sexual
function
— 2.25 (0.80e3.69),
P < .0001
Clopper et al,29
1993
9/9 4 16e21 <8 nmol/L TE 200 mg/2 wk Crossover Specific questions
on sexual
function and
NPT
— 0.40 (0.53 to 1.33),
P ¼ .40
Chiang et al,30
2009
20/20 12 20e75 <8 nmol/L TG 50 mg/d Parallel IIEF-15 score 0.90 (0.25e1.55),
P ¼ .01
0.56 (0.07 to 1.19),
P ¼ .08
Giltay et al,87
2010
0.08 (0.21 to
0.37),
P ¼ .59
0.08 (0.21
to 0.37),
P ¼ .59
35e69 <8 nmol/L TU 1,000 mg/12
wk
Parallel IIEF-5 score 0.29 (0.02 to 0.60),
P ¼ .07
—
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322 Corona et almen whose sexual desire decreased during the 2-year follow-up
period showed a nearly 10% decrease in circulating T levels.9
Incidence of secondary hypogonadism in a 4.3-year follow-up
observational EMAS cohort was associated with new or wors-
ening of low libido, ED, and infrequent spontaneous erections.10
All these epidemiologic studies support the genuine association
between androgens and sexual desire in humans.
The presence of androgen receptors in distinct areas of the
human brain have been described as involved in the regulation of
the male sexual response. Among these, the most important
include the temporal, preoptic, hypothalamus, amygdala,
midbrain, frontal, and prefrontal areas and cingulate gyrus
(Brodmann area 24)11 (Figure 1).
Corona et al4 recently performed the largest meta-analysis
published thus far scrutinizing the role of TTh on several as-
pects of male sexual function. Data on the effect of TTh on the
libido component were available in 17 studies that together
enrolled 1,111 individuals12e30 (Table 1). Overall, TTh was
found to improve libido, but this was not confirmed in those
studies considering only eugonadal patients at enrollment (T
levels < 12 nmol/L), without any differences in studies enrolling
subjects with milder (T levels < 12 nmol/L) or more severe (T
levels < 8 nmol/L) forms of hypogonadism (Table 1). Meta-
regression analysis of the entire sample showed a trend toward
an inverse relation between baseline mean T levels and the effect
size on the libido component, which reached statistical signifi-
cance when studies enrolling eugonadal or mixed eugonadal and
hypogonadal subjects at baseline were excluded from the anal-
ysis.4 Decreasing T using gonadotropin-releasing hormone ana-
logs, as in healthy men for contraception purposes31 or in
patients with advanced prostate cancer,32,33 produced a negative
effect on libido.RECOMMENDATION 1
 T significantly contributes to the regulation of male sexual
desire (level 1A), and TTh can improve libido in hypogonadal
(total T level < 12 nmol/L) men (level 1A).
 T evaluation is strongly recommended in all men complaining
of decreased sexual desire (level 1A).
The role played by DHT in the control of male sexual desire
is contradictory. In fact, patients with congenital 5a-reductase
(5AR) type 2 deficiency (a rare genetic disorder characterized by
a decreased conversion of T into DHT) after puberty often have
normal sexual desire.34 In line with this evidence, the CHAMP
study did not report any association between mass-derived DHT
and sexual desire.9 However, recent evidence documented a
decrease of sexual desire in patients taking 5AR inhibitors
(5ARis), which cause a decrease in DHT circulating levels,
suggesting a direct role in the regulation of male sexual desire.35
Interestingly, in some cases, the decrease of sexual desire per-
sisted even after 5ARi was withdrawn.35 A possible explanation
is that blocking 5AR in the brain could impair other 5ARJ Sex Med 2016;13:317e337
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desire. In line with these data, there is significant corroborative
evidence that administration of non-aromatization androgens
such as DHT, nandrolone, or mesterolone can improve male
sexual function. Oral DHT undecanoate treatment of agonadal
men was reported to maintain sexual function for 9 weeks.36
Similarly, daily DHT gel administration for 6 months to men
with andropause symptoms and serum T levels lower than 15
nmol/L was more effective than placebo in restoring sexual
function.37
Much less is known about the role of estrogens in human male
sexual behavior.38 In men with normal T levels, the adminis-
tration of tamoxifen, an estrogen receptor antagonist, or testo-
lactone, an aromatase inhibitor, did not modify sexual
function.38 No remarkable sexual dysfunction was reported in
men affected by congenital estrogen deficiency, suggesting that
estrogens are not strictly necessary for normal male sexual
behavior.38 A double-blinded, placebo-controlled RCT evalu-
ating the effect of the non-aromatization androgen DHT on 114
healthy men older than 50 years showed no effect on any of 33
measurements of sexual function and mood, apart from a mild,
but significant, decrease in overall sexual desire, which was
reversible after treatment cessation.39 However, an unexpected
improvement in sexual desire and frequency of sexual activity
occurred during transdermal E2 treatment in subjects affected
by aromatase deficiency (a rare condition impairing estrogen
formation), suggesting a possible role of estrogen in regulating
male sexual desire.38 In addition, Finkelstein et al,40 in a
double-blinded, placebo-controlled experimental model of
gonadotropin-releasing hormone analog-induced hypogonadism
performed in 400 healthy men, showed that estrogen and T
deficiencies contributed to the decrease of sexual function. In
particular, the enrolled men were previously treated with goser-
elin acetate to suppress endogenous T and E2 production and
then randomly assigned to receive a placebo, T alone, or T gel
and anastrozole to suppress the conversion of T to E2. In the
group that received T alone, inhibition of estrogen synthesis
compared with intact estrogen synthesis was associated with
significant increases in the percentage of body fat, subcutaneous
fat area, intra-abdominal fat area, and significant decreases in
sexual desire and EF, confirming that E2 exerts an independent
effect on these variables.40
In contrast, data from the EMAS did not indicate any asso-
ciation between E2 and overall sexual function in middle-aged
and older men.41 Similar results were reported in the CHAMP
study and the TTrials.8,9 Hence, more data are advisable to
clarify the specific role of estrogen in male sexual function and, in
particular, in the control of sexual desire.RECOMMENDATION 2
 DHT and estrogens play a minor role in the regulation of male
sexual desire (level 2B).J Sex Med 2016;13:317e337 DHT and E2 evaluations are not recommended in men
complaining of decreased sexual desire (level 3B).DHEA and Other Adrenal Hormones
An age-dependent decrease of circulating DHEA and DHEAS
has been reported, suggesting a role for these adrenal hormones in
the age-dependent impairment of several biological functions,
including the sexual ones.42,43 Granata et al44 evaluated sexual
function in a small prospective study involving 12 subjects with
autoimmune primary adrenal insufficiency who were studied
before (baseline) and after 2 months of adrenal hormone supple-
mentation. They found that DHEAS levels did not correlate with
any of the sexual parameters studied, including sexual desire, at
baseline or in the recovery phase. Granata et al44 also reported that
subjects with adrenal insufficiency had lower scores in all domains,
including sexual desire (as measured by the International Index of
Erectile Function [IIEF]), which were normalized after replace-
ment with cortisol and aldosterone. However, the improvement of
the sexual desire domain was not confirmed after the adjustment
for cortisol and renin levels during the recovery phase, suggesting
an indirect, if any, role of the gluco- and mineralocorticoids in
regulating male sexual desire.44
Several uncontrolled studies have indicated a positive effect of
DHEA administration on sexual functions, including libido.51
Corona et al45 recently published a meta-analysis of placebo-
controlled RCTs evaluating the effect of DHEA administration
in elderly men. They found that DHEA did not significantly
improve sexual desire in aging men. Similar results were reported
in a recent double-blinded, placebo-controlled RCT enrolling 21
men with hypoactive sexual desire.46
The European Registry on Cushing’s Syndrome documented
that excess cortisol was associated with a 69% decrease of libido
in affected men.47 However, it is unknown whether cortisol
played a direct role in the regulation of male sexual desire or
whether the latter relation was the result of the morbidities
associated with excess cortisol, including hypogonadism and
mood disturbances.47RECOMMENDATION 3
 Adrenal hormones, including DHEA and DHEAS (level 2A),
and cortisol and aldosterone (level 3B) are not involved in the
regulation of male sexual desire.
 Adrenal hormone evaluation is not recommended in men
complaining of decreased sexual desire (level 1A).Prolactin
An epidemiologic study conducted in middle-aged and elderly
European men did not demonstrate any association between
variation in PRL levels and sexual desire.48 However, in this study,
a low PRL level was associated with a negative change in sexual
functioning compared with the previous year.48 In apparent
AB
Figure 2. Role of testosterone in the mechanism of penile erection. Panel A depicts the generation of NO by NOS in NANC neurons (nNOS) or
endothelial cells (eNOS).This step is positively regulated by testosterone. NO diffuses into smoothmuscle cells and activates sGC, which in turn
transformsGTP into cGMP. cGMPactivatesPKG,which, through the indicated pathways, decreases intracellularCa2þ levels, leading to relaxation.
PDE5 metabolizes cGMP into GMP, thereby limiting its effects. The latter event is positively controlled by testosterone. Panel B depicts the
generation of InsP3 by NA binding to a1-receptors. InsP3, by increasing Ca
2þ levels, activates CLCAs, resulting in membrane depolarization and
the opening of VOC. Increased Ca2þ flowpromotes, through calmodulin, activation ofMLCKand cell contraction. Cell contraction also is obtained
by a second pathway, RhoA/ROCK, which increases, through a series of kinase activations, the sensitivity of MLC to Ca2þ. Testosterone is
supposed to negatively regulate the latter event. Adapted from Corona and Maggi.61 ATPase ¼ adenosine triphosphatase; Ca2þ ¼ intracellular
calcium; CC ¼ corpora cavernosa; cGMP ¼ cyclic guanosine monophosphate; CLCAs ¼ Ca2þ-sensitive chloride channels; eNOS ¼ endothelial
nitric oxide synthase; GAPs ¼ Rho1-GTP activating proteins; GEFs ¼ guanine nucleotide-exchange factors; GTP ¼ guanosine triphosphate;
InsP3 ¼ inositol 1,4,5-trisphosphate; MLC ¼ myosin light chain; MLCK ¼ myosin light chain kinase; MLCP ¼ myosin light chain phosphate;
NA¼ noradrenaline; NANC¼ non-adrenergic and non-cholinergic; nNOS¼ neuronal nitric oxide synthase; NO¼ nitric oxide; NOS¼ nitric oxide
synthase; P ¼ phosphate; PDE5 ¼ phosphodiesterase type 5; PKG ¼ protein kinase G; sGC ¼ soluble guanylate cyclase; SR ¼ sarcoplasmic
reticulum; VOC ¼ voltage-operated channels. Figure 2 is available in color online at www.jsm.jsexmed.org.
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severely decreased libido was associated with a 10 times higher
chance of having severe hyperprolactinemia (SHPRL; defined as
PRL > 735 mU/L or 35 ng/mL), whereas no association was
observed betweenmild hyperprolactinemia (defined as PRL> 420
mU/L or 20 ng/mL and < 735 mU/L or 35 ng/mL) and low
desire.49 Similar data were reported in amore recent study aimed at
identifying risk factors related to primary decreased libido (ie, not
associated with known conditions causing low libido, such as
hypogonadism, hyperprolactinemia, psychopathology, and/or
psychoactive medications) or secondary decreased libido (ie,
associated with these conditions), involving more than 3,700 men
with sexual dysfunction.2 In subjects with SHPRL, decreased li-
bido was almost universally present (84.2%), whereas only fewer
than 1%of patients consulting for sexual dysfunction had SHPRL.
However, in this cohort, two of three subjects with SHPRL had a
pituitary tumor or some other organic problem; therefore, such
patients must be identified.2,49
The mechanisms by which PRL regulates male sexual desire
are not completely understood (Figure 1). A PRL-induced
hypogonadism could explain, at least in part, the association
between SHPRL and decreased libido.42 In fact, PRL acutely
increased the turnover of dopamine (DA) in several brain areas
partly involved in the regulation of sexual behavior (ie, nigros-
triatal and mesolimbic tracts) and of PRL secretion (ie, tuber-
oinfundibular tract).1 In particular, in the tuberoinfundibular
tract, chronic hyperprolactinemia resulted in an increase in DA
secretion leading to suppression of gonadotropin-releasing hor-
mone, low luteinizing hormone, and low T.1,42 Accordingly,
SHPRL-induced central hypogonadism is a common finding.
However, a direct effect of increased PRL on sexual desire also
was hypothesized.1,42 In fact, PRL receptors were found in the
diencephalic incertohypothalamic dopaminergic system, a
pathway of short axons with terminals in the medial preoptic
area, the most important area for the control of motivational and
consummatory aspects of sexual behavior.1,42 In the incertohy-
pothalamic dopaminergic system in contrast to other areas, PRL
inhibited, or did not increase, DA activity, supporting a direct,
negative effect of PRL on sexual motivation.1,42,50
A detailed list of causes of hyperprolactinemia has been re-
ported elsewhere.42
DA agonists (bromocriptine and cabergoline) are the first
choice in treating hyperprolactinemia, in particular PRL-
secreting adenomas, because of their higher efficacy in normal-
izing PRL levels and a higher frequency of pituitary tumor
shrinkage.42 In most cases, these PRL-lowering agents normalize
hypoactive sexual desire, in addition to PRL and T levels. After
treatment with dopaminergic drugs, hypoactive sexual desire
normalizes in almost 70% to 90% of patients.42
As mentioned earlier, DA plays a crucial role acting as a
neurotransmitter in regulating sexual excitation, particularly at the
hypothalamic and mesolimbic levels.11 Accordingly, many pa-
tients are treated off label with DA agonists to help increase sexualJ Sex Med 2016;13:317e337desire. Despite this evidence, the specific role of DA in regulating
male sexual desire is not completely clear. The best clinical example
in this regard is represented by patients with Parkinson disease
(PD). Sexual dysfunction and decreased libido, in particular, are
common in patients with PD and it is closely associated with
depression and relationship dissatisfaction.51 In addition, the use
of DA agonist has been associated with an improvement of sexual
desire and with impulse control disorders, a frequent complication
of PD, with an estimated prevalence of 3% to 4%.51,52 Never-
theless, it is not clear whether the known brain “lesions” related to
PD (supposedly relevant for maintaining normal sexual function)
have a decisive impact on the prevalence of sexual dysfunction
observed in PD.51 In fact, Lipe et al53 reported no difference in the
prevalence of sexual dysfunction when PD was compared with
another, non-neurologic, chronic disease such as arthritis, sug-
gesting that factors other than DA impairment might play a more
important role. In support of this notion, Kummer et al54 reported
that age and depressive symptoms were the main predictors of loss
of libido in patients with PD.RECOMMENDATION 4
 PRL plays a major role in regulating male sexual desire (level
2A), acting through direct and indirect pathways (level 3B).
 PRL levels should be evaluated in all men complaining of
decreased sexual desire (level 2A).
 Treating hyperprolactinemia restores sexual desire (level 2A).
Thyroid Hormones
Hypothyroidism in men is another endocrine condition
previously associated with decreased libido. In a small pro-
spective study, Carani et al55 evaluated the prevalence of sexual
dysfunctions in 48 men, 34 with hyperthyroidism and 14 with
hypothyroidism, and their possible remission after normalizing
TH levels. They found that low sexual desire was related to
hypothyroidism and that it was restored after TH therapy. The
mechanism of action of TH on sexual desire is unknown.
Although a hypothyroidism-induced increase in PRL42 might
mediate the negative effects of low TH on sexual desire, a
direct role of TH on the serotoninergic system has been
postulated.55 More recently, Corona et al56 confirmed the as-
sociation between low sexual desire and hypothyroidism in two
different populations of subjects, including the aforementioned
EMAS cohort and more than 3,000 patients consulting for
sexual dysfunction. Hence, more studies are advisable to
confirm the possible role of THs in the control of male sexual
desire.
RECOMMENDATION 5
 The contribution of THs in the regulation of male sexual
desire is contradictory (level 3B).
 TH evaluation is not recommended in men complaining of
decreased sexual desire (level 2B)
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Sex Steroids (T, DHT, and E2)
Role of T: Summary of Evidence From Experimental Studies
Androgens are considered the major hormonal regulator of
penile development and physiology57 (Figure 1). In humans, T
influences penile development, mainly because of extracellular
stromal expansion.58 Postnatal penile length and growth rate
also seem to be correlated with the T surge occurring in the first
months of life (mini-puberty).59 However, no further correla-
tion is seen in postpubertal adults. Most studies agree that
androgen sensitivity and androgen receptor expression vary
with age and stage of penile development. As a result, the role of
T in adult ED has been the object of several controversies. Most
early studies focused on androgen ablation in animal models, a
condition that can hardly be transferred to the human physi-
ology of an erection, with the few exceptions of bilateral or-
chiectomy for testicular cancer and androgen deprivation for
prostate cancer. However, some recent studies on hypo-
gonadism induced by a high-fat diet recapitulated the findings
from castration studies.59,60
Part of the erectile response to T is mediated through an
increased sexual desire, but several experimental studies have
documented a direct role of T on cavernous SMCs involving
NO, PDE5, RhoA-ROCK, cavernosal nerve function, and
adrenergic response (Figures 1 and 2).61
All experimental studies agree on a castration-induced decrease
in intracavernous pressure caused by decreased arterial inflow and
altered veno-occlusion during erection. Although the data from
surgical hypogonadism hardly represent a very small minority of
cases of human male hypogonadism, the animal model of
hypogonadism induced by a high-fat diet seems to recapitulate
the findings of castration studies. The NO pathway clearly rep-
resents a major target of androgens62,63 (Figure 2); however,
studies of animals treated with L-N G-nitro arginine methyl ester
also found additional NO-independent mechanisms that still
required intact cGMP generation to control veno-occlusion.64
Among the NO-independent targets of androgens is the RhoA-
ROCK pathway65 that keeps SMCs stably contracted by cal-
cium sensitization; hypogonadism has been shown to induce
activation of ROCK1,60 counteracting SMC relaxation, but not
ROCK2, which, conversely, is increased by T in endothelial
cells66 (Figure 2). Another NO-independent mechanism is the
regulation of smooth muscle myosin isoforms,67 and impaired
renewal of subtunical cells also has been described in hypo-
gonadism, contributing to impaired veno-occlusion.68 Several,
but not all,69 studies found that PDE5 expression was regulated
by androgens63,70,71 (Figure 2). In general, experimental studies
converge in showing that androgens are necessary to sustain the
NO-cGMP pathway through direct70,71 or indirect72 mecha-
nisms.73 A recent study reported that estrogens inhibit, more
than androgens stimulate, PDE5 expression and activity.73Another recognized mechanism of androgen action is the regu-
lation of a1-adrenergic responsiveness of SMCs
63,74 (Figure 2).
Consistent findings have pointed toward an effect of T on post-
ganglionic parasympathetic neurons or, even further upstream,
within the autonomic nervous system.75 Therefore, androgens
appear necessary to support adequate neuronal stimulation to the
corpora cavernosa and maintain structural integrity in tissue as seen
after the denervation from prostate surgery in men.68,75RECOMMENDATION 6
 T regulates penile development and growth in early life, but
not after puberty (level A).
 T targets several molecular pathways involved in the physiology
of erections, including the NO-cGMP pathway (level A),
RhoA-ROCK signaling, adrenergic response, and cavernous
SMC turnover (level B).
Role of T: Summary of Evidence From Clinical Studies
Human studies are extremely heterogeneous in their assess-
ment of EF; for the present synthesis, “overall EF” includes
sexual-related and spontaneous erections, whereas “sexual-related
EF” refers to the function exclusively assessed in the context of a
sexual encounter (Sexual Encounter Profile, IIEF, and others).4
The EMAS and other cross-sectional surveys have reported
lower T levels in approximately 30% of men with ED.6,7,39,76e79
Longitudinal studies have confirmed this association by showing
that an individual’s decrease (change [D]) to the hypogonadal
range, rather than its absolute value, predicts sexual decline.9
However, this relation is weaker for EF compared with desire
and still does not imply any causal association.9,79
Early studies found that the androgen dependency of EF in young
men was maintained at threshold values that were far below those
required to maintain the function of other target organs.80 However,
this finding does not automatically translate to elderly men with
comorbidities (ie, the vast majority of men complaining of ED). Of
note is that aging is associated with an increase in SHBG that can
lower bioavailable T. This suggests that free T could be a better
predictor of the association between EF and androgens. Although in
principle this works, the direct measurement of free T, or its calcu-
lation by SHBG, is disadvantaged by the reliability vs. costs of proper
assays and uncertainties in SHBGpolymorphism and its affinity toT.
In the past, most studies were performed using total rather than free
T, and the EMAS7 did not show a superiority of one or the other.
Nevertheless, more data collected with an accurate direct measure-
ment of freeT in the future could indicate a stronger prediction of EF.
The few available RCTs addressing the role of T on ED have been
extensively reviewed, with the largest andmost updatedmeta-analysis
confirming significant beneficial effects on overall EF, but only in
men with a T level lower than 12 nmol/L.4 Regression and subgroup
analyses have emphasized a role for aging as a possible moderator of
ED responsiveness to T. Specifically, data on sexual-related EFJ Sex Med 2016;13:317e337
Table 2. Characteristics and Outcomes of Phase 1 and 2 Studies Evaluating Effects of Oxytocin or a-MSH Analogs on Several Sexual Function Parameters
Study
Sample
size
Population
studied Age (y) Drug
Duration of
treatment Type of study Erectile response Side effects
Oxytocin
Behnia et al,98
2014
— 29 Healthy
heterosexual
couples
— Intranasal oxytocin
application (24 IU)
Acute Single arm Psychometric
questionnaires,
[orgasm,
[sexual satiety
e
Burri et al,99
1998
e 10 Healthy men — Intranasal oxytocin
application (24 IU)
Acute Double-blinded,
placebo-
controlled,
balanced
crossover
ASES, equivocal
effects on sexual
behavior
—
Scheele
et al,100
2013
— 20 Healthy non-
smoking
male
volunteers
25.5 Intranasal oxytocin
application (24 IU)
Acute Double-blinded,
discovery and
replication study
MRI, female
partner’s face
more attractive
vs unfamiliar
women,
augmented
neural response
to partner vs.
familiar woman
—
MSH analog
Royalty et al,
101 2014
Single-dose trial
design (part
1)
6 Healthy
overweight
and obese
subjects
35.2 Long-acting a-MSH
analog (0.03 mg/
kg) MC4-NN2-
0453
22 d Randomized, double-
blinded, placebo-
controlled, 2-part
trial
Erectile
improvement
(self-reported)
Skin hyperpigmentation
(33%), headache
(30%), decreased
appetite (12%),
injection-site
hemorrhage
6 32.3 Long-acting a-MSH
analog MC4-NN2-
0453 (0.06 mg/kg)
6 39.3 Long-acting a-MSH
analog MC4-NN2-
0453 (0.15 mg/kg)
6 35.2 Long-acting a-MSH
analog MC4-NN2-
0453 (0.30 mg/kg)
7 37.6 Long-acting a-MSH
analog MC4-NN2-
0453 (0.60 mg/kg)
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Table 2. Continued
Study
Sample
size
Population
studied Age (y) Drug
Duration of
treatment Type of study Erectile response Side effects
6 35.0 Long-acting a-MSH
analog MC4-NN2-
0453 (1.00 mg/kg)
6 31.8 Long-acting a-MSH
analog (1.50 mg/kg)
Multiple-Dose
Trial Design
(Part 2)
25 Healthy obese
subjects
43.8 Long-acting a-MSH
analog MC4-NN2-
0453 (0.75 mg/d)
210 d
50 38.6 long-acting a-MSH
analog MC4-NN2-
0453 (1.50 mg/d)
25 41.4 long-acting a-MSH
analog MC4-NN2-
0453 (3.00 mg/d)
Rosen et al,102
2004
Phase 1 study
(SC 0.3, 1, 3,
5, 7.5, 10 mg)
36 Healthy men 33.6 Melanocortin receptor
agonist PT-141
Acute Randomized,
double-blinded,
placebo-
controlled, 2-
phase trial
RigiScan, [duration
of rigidity > 60%
(min), [duration
of rigidity > 80%
(min; for dosage
1 mg)
Nausea, headache,
flushing (average
30% of population
for higher dosages)
Phase 2 study
(SC 4e6 mg)
25 Patients with
ED not
responsive to
sildenafil
48 Melanocortin receptor
agonist PT-141
RigiScan, [duration
of rigidity > 60%
(min), [duration
of rigidity > 80%
(min)
Diamond
et al,103
2004
Phase 1 study,
nasal spray
(4, 7, 10, 20
mg)
24 Healthy
subjects
33.5 Melanocortin receptor
agonist PT-141
Acute Randomized,
double-blinded,
placebo-
controlled, 2-
phase trial
RigiScan, [duration
of rigidity > 60%
(min), [duration
of rigidity > 80%
(min)
Nausea, flushing
Phase 2 study,
nasal spray
(7e20 mg)
24 Patients with
ED
responsive to
sildenafil
50.9 RigiScan, [duration
of rigidity> 60%
(min), [duration
of rigidity> 80%
(min)
(continued)
J
S
ex
M
ed
20
16
;13:317
e
337
328
Corona
et
al
Table 2. Continued
Study
Sample
size
Population
studied Age (y) Drug
Duration of
treatment Type of study Erectile response Side effects
Wessells
et al,104
2000
— 10 Psychogenic ED 47.4 Melanotan II 0.025 ±
0.157 mg/kg
Acute Double blinded,
placebo-
controlled
crossover
RigiScan, [duration
of rigidity > 80%
(min), [sexual
desire
12 with severe nausea
(12.9% of subjects)
10 Organic ED 56.2 Nausea with stretching
or yawning
Wessells
et al,105 1998
— 10 Psychogenic ED 47 Melanotan II (0.025
mg/kg)
Acute Double-blinded,
placebo-
controlled
crossover study
RigiScan, [duration
of rigidity > 80%
(min)
Transient nausea with
stretching and
yawning
Safarinejad
et al,106
2008
— 342 Patients with
ED not
responsive to
sildenafil
28e59 Intranasal
bremelanotide 10
mg
Double-blinded,
placebo-
controlled study
IIEF score, [sexual
satisfaction
domain
—
Krishna
et al,107
2008
Treatments
(placebo;
200-mg
single oral
dose of MK-
0493; 500-
mg single oral
dose of MK-
0493; 50-mg
single oral
dose of
sildenafil)
20 Organic ED 35e50 Melanocortin 4
receptor agonist
(MK-0493)
Acute Randomized, double-
blinded, placebo-
controlled, 4-
period crossover
study
RigiScan, [duration
of rigidity > 60%
(min)
Nausea, vomiting
ASES ¼ Acute Sexual Experience Scale; ED ¼ erectile dysfunction; IIEF ¼ International Index of Erectile Function; MRI ¼ magnetic resonance imaging; MSH ¼ melanocyte-stimulating hormone;
SC ¼ subcutaneous.
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330 Corona et alwere available in 19 studies enrolling 1,431 individu-
als12e18,21e26,30,81,125e130 (Table 1). Overall, TTh determined
an improvement only in studies enrolling hypogonadal subjects
(mean baseline T levels < 12 nmol/L), but not in those investi-
gating eugonadal patients or mixed eugonadal and hypogonadal
subjects. A sensitivity analysis performed in the few trials (n¼ 6)
using IIEF-EF domain score as an outcome measurement
confirmed the positive effect of TTh on the sexual-related EF
component (IIEF-15 EF subdomain D increase of 3.726, 95%
CI ¼ 1.621e5.830, P < .001).
More recently, the concept of “compensated” or “subclinical
hypogonadism” has been introduced, suggesting that when T
decreases from a previously higher level, the increase in lutei-
nizing hormone might become a confirmatory biomarker for
insufficient androgenization.82e84 Another relevant emerging
aspect is the time course of T effects (ie, length of treatment
necessary to achieve the maximum result). Recent systematic
reviews85 and RCTs25,80,81 have found that although the effects
on libido, ejaculation, and sexual activity occur within just 2 to 3
weeks, effects on EF could require up to 6 or even 12 months.RECOMMENDATION 7
 The decrease of circulating T level is associated with a decrease
in EF (level 2B).
 TTh in hypogonadal men (total T level < 12 nmol/L) is
associated with significant increases in self-reported measure-
ments of EF that are proportional to the severity of hypo-
gonadal status before treatment (level 1A).
 Basal and longitudinal assessments of T are recommended in
men with ED (level 1A).
Role of DHT
DHT is the most potent androgen involved in genital tissue
development. No major discrepancies could be found when
comparing the in vitro effects of T and DHT on EF. However,
interest in the role of DHT has been renewed recently by pa-
tients complaining of sexual-related symptoms after exposure to
5ARis.86 Studies have pointed toward a drug-related, rather than
DHT-mediated, effect. In animal models, 5ARis have been
associated with structural and functional alterations in penile
tissue contributing to penile fibrosis that is mainly exerted
through a modulation of cholinergic and adrenergic sensitivity,
with no apparent change in PDE5.87 However, the available
evidence is insufficient to determine whether defective DHT, in
the presence of normal T, impairs EF in men. The few trials
performed on hypogonadal subjects treated with DHT alone or
T plus 5ARi found similar effects on major EF domains.37,88RECOMMENDATION 8
 DHT exerts qualitatively similar effects as T on EF (level 2A),
but it has been less extensively studied. Treatment using DHT and its analogs (mesterolone) cannot
be recommended as an alternative to TTh to improve EF in
hypogonadal men (level 4B).
 Measurement of DHT is not recommended in the assessment
of EF (level 3A).
Role of Estrogens
E2 was found to be required to maintain male sexual func-
tion in some, but not all, studies of selective estrogen defi-
ciency.36,41 The EMAS showed that E2 correlated with
psychological symptoms of male aging,41 but not with EF
domains, confirming previous findings.5,89 These studies found
a robust, independent correlation between E2 and sexual
dysfunction-associated distress and T associated with somatized
anxiety in older men with ED.90 A recent RCT found that
aromatization played only a minor role in the maintenance of
sexual function in healthy men, with some dependence on
increasing age and obesity.39 More recently, a longitudinal
study found an association between estrone and the onset of
ED during a 2-year follow-up.9 Measurement of estrogens in
men is not reliable with immunoassays; therefore, their use as
biomarkers is possible only if adequate detection systems are
available.RECOMMENDATION 9
 The role of E2 on EF is controversial. Experimental evi-
dence indicates that E2 downregulates PDE5 expression
(level 3C).
 Measurement of estrogens is not recommended in the assess-
ment of EF (level 2C).DHEA and Other Adrenal Hormones
Past evidence documented a possible role of an age-
dependent decrease of DHEAS in the pathogenesis of
ED.42,43 The MMAS found that DHEAS was the only hor-
mone negatively correlated to the prevalence of ED among 17
investigated hormones, including T and E2.91 In addition,
Basar et al,92 in a consecutive series of 348 men, reported that
DHEAS and free T levels were significantly lower in men with
sexual dysfunction as determined by the IIEF score. However,
more recent data have advocated against an association between
DHEA (and its DHEAS) and ED. A large placebo-controlled
RCT evaluating the effect of DHEA in elderly men and
women with an observational period up to 2 years failed to
demonstrate a physiologically relevant beneficial effect on
ED.93 Similarly, Morales et al94 reported that DHEA treatment
(50 mg twice daily) did not induce significant differences in
sexual performance outcomes compared with placebo as
assessed by the IIEF, the Androgen Deficiency in the Aging
Male questionnaire, the Aging Male Symptom Scale, and the
Global Assessment Questionnaire. Similarly a meta-analysis
evaluating the effect of DHEA administration in elderly menJ Sex Med 2016;13:317e337
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overall score of the IIEF-15 or EF domain total score.45
The prevalence of ED in patients with Cushing syndrome is
unknown. In particular, no information has been reported in the
European Registry on Cushing’s Syndrome.47 Granata et al44
found that in subjects with adrenal insufficiency, treatment
with glucocorticoids and mineralocorticoids independently
improved the EF domain of the IIFF.RECOMMENDATION 10
 DHEA and DHEAS are not involved in the regulation of male
EF (level 2A).
 Glucocorticoid and mineralocorticoid in adrenal insufficiency
might play a role in restoring EF (level 4C).
Prolactin
The relation between hyperprolactinemia and EF is under
debate. Some researchers have suggested a possible pathogenic link
between severe ED and SHPRL.42However, Corona et al49 did not
confirm a significant association between SHPRL and severe ED
after adjustment for confounders, including T levels. Hence,
SHPRL-induced hypogonadism could explain, at least in part, the
association between ED and SHPRL. In apparent contrast with
these findings, the same group reported that in subjects with sexual
dysfunction, low PRL (<10 ng/mL or 210 mU/L) was associated
with arteriogenic ED.95 This finding was confirmed in the Euro-
pean general population by the EMAS.48 Some experimental
studies have indicated that acute, but not chronic, pharmacologic
elevation of brain PRL is associated with a facilitated, rather than an
impaired, sexual behavior, including increased penile erection,
mounting, and intromission activity.42 Similarly, in a population-
based birth cohort study of men from the Philippines, basal PRL
was inversely related to mating effort as indicated by the number of
the men’s lifetime sexual partners and the sexual activity in the
month preceding the PRL measurement.96 In that study, men
without offspring who reported no sexual activity and/or the
smallest number of sexual partners had the lowest concentrations of
PRL.96 All these findings indicate that PRL might have a more
positive, than negative, effect on initiating or maintaining sexual
behavior. It is still unclear how PRL might facilitate male sexual
behavior. Differentmechanisms could be advocated to explain these
associations. In fact, low PRL in the peripheral circulation could
mirror, within the hypothalamus, an increase of dopaminergic or a
decrease of serotoninergic signaling. The latter possibility represents
the most intriguing hypothesis.RECOMMENDATION 11
 PRL does not play a direct role in the regulation of male EF
(level 3B).
 PRL evaluation is not recommended in patients complaining
of ED (level 2B).J Sex Med 2016;13:317e337 Treating hyperprolactinemia might have indirect, positive ef-
fects on arousal and erection (level 3B).
Oxytocin
OT is a nonapeptide synthesized in the supraoptic and para-
ventricular nuclei of the hypothalamus and released by the pos-
terior pituitary. In contrast to its clear function in female
reproduction (regulation of milk ejection reflex and uterine
contractility), the physiologic role in men is unclear. Animal
models have indicated that OT plays a key role in the central
control of penile erection, at the level of the paraventricular nuclei
of the hypothalamus and of the spinal cord.97 In particular, OT
increases the activity of mesolimbic and mesocortical dopami-
nergic neurons originating in the ventral tegmental area and
projecting to the nucleus accumbens and to the medial prefrontal
cortex.97 Accordingly, mesolimbic and mesocortical dopami-
nergic neurons play a key role in the motivational and rewarding
properties of natural reinforcing stimuli, including sexual activ-
ity.97 The mechanism by which OT induces penile erection and
activates mesolimbic dopaminergic neurons when injected into
the ventral subiculum or into the posteromedial nucleus of the
amygdala is only partly understood. In these areas, OT also acti-
vates its own receptors that lead to the activation of NO synthase,
thereby increasing NO production. NO in turn activates un-
known efferent projections, which apparently increase gluta-
matergic neurotransmission in the ventral tegmental area.97 In
particular, DA released from these neurons is believed to mediate
the transposition of the motivational aspects of natural stimuli
into goal-directed behaviors, as in sexual activity, seeking a sexual
partner, and sexual intercourse to achieve reward and satisfac-
tion.97 Altogether, these neural pathways might constitute a
complex hypothetical circuit, which plays a role not only in the
consummatory phase of sexual activity (EF and copulation) but
also in the motivational and rewarding aspects of the anticipatory
phase of sexual behavior.
Despite this strong experimental evidence, knowledge about the
effects of OT on human sexual behaviors and partner interactions is
scanty (Table 2).98e107 In an uncontrolled observational study
involving 29 healthy heterosexual couples, Behnia et al98 analyzed
the acute effects of intranasally administered OT (24 IU) on drive,
arousal, orgasm, and refractory aspects of sexual behavior, together
with partner interactions. They reported that men indicated higher
levels of sexual satiety after sexual intercourse and women felt more
relaxed and subgroups indicated an increased ability to share sexual
desires or to empathize with their partners. However, the effect was
small to moderate. In a previous small RCT with the same dose of
OT administered intranasally, a lack of effect of active treatment
was found on several sexual parameters, including arousal.99 In a
double-blinded, placebo-controlled RCT, a specific effect of
intranasal OTwas found in perceiving the partner as attractive, with
magnetic resonance imagingederived activation of brain regions
involved in reward, such as the ventral tegmental area and the
nucleus accumbens, but without a specific effect on arousal.100
332 Corona et alHence, there is a growing idea that OT in humans is important in
pair bonding and in enhancing attractiveness during romantic love,
as found in other mammals.100RECOMMENDATION 12
 Conclusive data regarding the potential therapeutic role of OT
in male sexual dysfunctions are lacking (level 2B).
Growth Hormone
GH is a 191-amino acid polypeptide synthesized and secreted
under the control of GH-releasing hormone (positive) and so-
matostatin (negative) of somatotroph cells in the anterior pitui-
tary. Its primary role is to promote linear bone growth. The
physiologic role of GH on sexual function has not been fully
elucidated. Experimental studies have shown that GH can induce
dose-dependent relaxation of human corpus cavernosal strips
in vitro and an increase in cGMP,108,109 but the GH concen-
tration needed to elicit a 30% relaxation was at least three orders
of magnitude higher than the GH concentration changes
recorded in cavernosal blood sampling during the physiologic
process of erection in men.110 Pastuszak et al111 reported that
IGF-1 levels correlated with sexual function score in 65 men
scheduled for radical prostatectomy. In contrast to these findings,
Miwa et al112 did not find any correlation between peripheral
GH levels and all aspects of the Aging Male Symptom Scale
including sexual function in ambulatory men. In a small series of
patients, cavernous GH levels in organic and psychogenic ED
did not differ from peripheral levels.113
Although ED and decreased libido are often reported as symp-
toms of acromegaly in textbooks,114 it is still unclear whether this is
due to the excess of GH or a consequence of GH-related mor-
bidities including secondary hypogonadism. Recently, Lotti
et al115 published the first study that systematically analyzed EF in
57 subjects with acromegaly. Although 42.1% of patients analyzed
complained of ED, it was not related to several acromegaly-related
parameters, including IGF-1 levels, type of treatment, duration of
disease, or secondary hypogonadism. Conversely, subjects with
ED and acromegaly had higher cardiovascular risk factors and
worse impairment of penile vascular flow compared with subjects
with acromegaly and without ED.115 These data indicate that ED
in acromegaly is not related to abnormalities of GH or IGF-1 or T
levels but is associated with cardiac morbidities related to the dis-
ease. Hence, exposure to excess GH probably does not directly
affect EF in vivo and caution is needed when results obtained by
in vitro studies are transposed in vivo to humans. In line with these
findings, GH replacement treatment did not modify sexual func-
tion in men with GH deficiency.116RECOMMENDATION 13
 GH and IGF-1 are not involved in the regulation of male EF
(level 3B). GH and IGF-1 levels should not be evaluated in men com-
plaining of ED (level 2B).
Melanocortin
Melanocortins are a family of peptide hormones, including
adrenocorticotrophic hormone and a-, b-, and g-MSHs, derived
from the cleavage of a large precursor peptide, namely pro-
opiomelanocortin. Experimental animal models indicated that
the interaction of a- and b-MSH with specific melanocortin re-
ceptors (MCR3 and MCR4) within the hypothalamus and limbic
system led to a typical behavioral syndrome including grooming,
stretching, and yawning, spontaneous penile erection and ejacu-
lation, and increased sexual receptivity.117 Two synthetic analogs
of a-MSH have been developed for human use (melanotan; afa-
melanotide, formerly CUV1647; and bremelanotide, formerly
PT-141). Phase 1 and 2 trials have been completed and are pre-
sented inTable 2101e107 (for review, seeÜckert et al117).However,
in all studies, drug-related adverse effects were present, such as
nausea, yawning, and flushing, which limited the attractiveness of
this treatment. In addition, there were concerns regarding a
possible increase in blood pressure.117RECOMMENDATION 14
 Animalmodels indicate that themelanocortin system is involved
in the regulation of EF acting at a central level (level 2C).
 Available RCTs do no suggest analogs of a-MSH for the treat-
ment of ED because of associated adverse events (level 1B).
Thyroid Hormones
Although thyroid dysfunctions are often highlighted as com-
mon ED-associated conditions,42 only a few evidence-based re-
ports have investigated this aspect. In 2005, in a small Italian study,
Carani et al55 documented that hypo- and hyperthyroidism were
commonly associated with ED (as detected by validated ques-
tionnaires). Similar results were confirmed in two other small
studies from Italy118 and Greece.119 Interestingly, Carani et al55
and Krassas et al119 further documented that the correction of the
underlying thyroid disorders restored EF. More recently, Corona
et al56 evaluated the relation between TH and EF in a large series
(N¼ 3,203) of patients seeking medical care for sexual dysfunction
and in the EMAS population. They found that hyperthyroidism,
but not hypothyroidism, was associated with an increased risk of
severe ED, after adjusting for confounding factors, including T and
PRL levels.These associationswere confirmed innested case-control
analyses comparing subjects with overt hyperthyroidism with con-
trols matched for age, body mass index, smoking status, and T
levels.56 Similarly, in a retrospective analysis of a health insurance
database representative of Taiwan’s general population, Keller
et al120 reported that subjects with ED were 1.64 times more likely
to have been previously diagnosed with hyperthyroidism compared
with control individuals without ED. TH-a and TH-b receptors
were described in rat and human corpora cavernosa endothelial cellsJ Sex Med 2016;13:317e337
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indicated an impairment of NO-dependent relaxation of corpora
cavernosa.123 In rabbit corpora cavernosa strips, relaxation induced
by acetylcholine and electrical field stimulation was impaired,
whereas sensitivity to the NO donor, sodium nitroprusside, was
unchanged.123 These data suggest an effect of TH in penile NO
formation, which has been demonstrated in a rat model.125
Therefore, hyperthyroidism-associated ED could be due to a
direct effect of TH on penile cognate receptors (for review, see
Krassas et al123). Despite this evidence, Maseroli et al124 reported
that the prevalence of thyroid disorders in patients seeking medical
care for ED was rather low (<1%) and not different from that
observed in the general population of the same geographic area.RECOMMENDATION 15
 Hyperthyroidism is significantly associated with an increased
risk of ED (level 3B).
 Treating hyperthyroidism improves ED (level 3B).
 Sexual function should be assessed in all men with hyperthy-
roidism (level 3B).
 The prevalence of hyperthyroidism in men seeking medical
care for ED is low (level 2B).
 TH evaluation is not recommended in all men complaining of
ED (level 2B).
 The association between hypothyroidism and impairment of
EF is contradictory (level 2C).
 Sexual function should not be assessed in all men with hy-
pothyroidism (level 2B).
 The prevalence of hypothyroidism in men seeking medical
care for ED is low (level 2B).
 TH evaluation is not recommended in all men complaining of
ED (level 2B).CONCLUSIONS
Several hormones modulate or even promote human sexual
behavior, including libido and arousal. Although epidemiologic
and intervention studies corroborate the crucial role of T in
inducing and maintaining sexual desire and erection, results for
other hormones are less clear. Hypothalamic neurohormones as
OT and a-MSH are currently under active research for thera-
peutic purposes. However, results from pilot studies are disap-
pointing for lack of consistency or for disappointing side effects.
Aside from hypogonadism, other endocrine disorders are asso-
ciated with sexual dysfunctions. However, apart from hyper-
prolactinemia, their investigation in men seeking medical care
for sexual dysfunction is not recommended because of the
current lack of convincing evidence.
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